ArticleBMC neurology2026
Efficacy and influencing factors of bevacizumab monotherapy and combination therapy in recurrent high-grade glioma: a twelve-year experience.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundGliomas are the most prevalent primary malignant brain tumors in adults, with high-grade gliomas (HGGs) characterized by elevated recurrence rates, aggressiveness, and mortality. Despite numerous therapies being assessed for rHGGs, most have not yielded satisfactory results. Bevacizumab inhibits tumor angiogenesis by targeting VEGF, and garnered significant attention for its efficacy. We conducted this retrospective study to analyze the prognosis of patients with rHGG undergoing bevacizumab-related therapy, and explored the influencing factors from the clinical, radiological, and molecular pathological perspectives.
methodsPatients diagnosed with rHGGs who received bevacizumab-related therapy from January 2012 to January 2024 were included in this study. Patients were divided into bevacizumab monotherapy and combination therapy groups. Clinical, radiological, molecular pathological, and survival data were collected for analysis.
resultsA total of 162 patients diagnosed with rHGGs were enrolled, including 115 patients receiving bevacizumab monotherapy and 47 patients receiving combination therapy. The median overall survival (mOS) was 10.3 months, and the median progression-free survival (mPFS) was 5.6 months, with no statistical difference observed in mOS and mPFS between the two treatment groups. In both univariate and multivariate analysis, patients over 60 years old exhibited a worse mOS after bevacizumab-related therapy, while multiple tumors suggested a worse mPFS.
conclusionsThis study focused on bevacizumab-related therapy in rHGGs, and the result indicated no apparent survial advantage with the addition of combination therapies to bevacizumab. Younger patients and those with single recurrent lesion were more likely to benefit from bevacizumab-related therapy. Identification of subgroups that benefit from bevacizumab-related therapy may represent a promising avenue for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.